黑料福利社 Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
| Press release
News & Events
黑料福利社 Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline
| Press release
黑料福利社 Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need
| Press release
黑料福利社 Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025
| Press release
黑料福利社 to Announce First Phase 1/2a Data for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO
| Press release
黑料福利社 Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
| Press release